Eli Lilly and Company (LLY) 10-Year Financial Performance & Capital Metrics

LLY • • Industrial / General

HealthcareLarge PharmaMetabolic & Endocrine SpecialistsDiabetes & Obesity Market Leaders

AboutEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.Show more

Revenue $45.04B +32.0%
EBITDA $19.27B +56.5%
Net Income $10.59B +102.1%
EPS (Diluted) 11.71 +101.9%
Gross Margin 81.31% +2.6%
EBITDA Margin 42.78% +18.5%
Operating Margin 38.86% +22.9%
Net Margin 23.51% +53.1%
ROE 84.26% +74.0%
ROIC 33.69% +21.2%
Debt/Equity 2.36 +1.5%
Interest Coverage 22.42 +1.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 65.1%
✓10 consecutive years of dividend growth
✓Strong 5Y sales CAGR of 15.1%
✓Healthy 5Y average net margin of 21.1%

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Expensive at 68.2x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y8.67%

5Y15.08%

3Y16.73%

TTM45.41%

Profit (Net Income) CAGR

10Y16.05%

5Y4.95%

3Y23.8%

TTM119.98%

EPS CAGR

10Y18.47%

5Y6.15%

3Y26.03%

TTM120.97%

ROCE

10Y Avg22.62%

5Y Avg28.88%

3Y Avg32.54%

Latest40.21%

Peer Comparison

Diabetes & Obesity Market Leaders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LLYEli Lilly and Company	964.11B	1077.19	91.99	32%	30.99%	77.2%	0.04%	2.36
NVONovo Nordisk A/S	200.9B	59.64	2.64	25.03%	32.88%	61.08%	34.67%	0.72

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.96B	21.22B	19.97B	21.49B	22.32B	24.54B	28.32B	28.54B	34.12B	45.04B
Revenue Growth %	0.02%	0.06%	-0.06%	0.08%	0.04%	0.1%	0.15%	0.01%	0.2%	0.32%
Cost of Goods Sold+	5.04B	5.71B	4.45B	4.68B	4.72B	5.48B	7.31B	6.63B	7.08B	8.42B
COGS % of Revenue	0.25%	0.27%	0.22%	0.22%	0.21%	0.22%	0.26%	0.23%	0.21%	0.19%
Gross Profit+	14.92B	15.51B	15.53B	16.81B	17.6B	19.06B	21.01B	21.91B	27.04B	36.62B
Gross Margin %	0.75%	0.73%	0.78%	0.78%	0.79%	0.78%	0.74%	0.77%	0.79%	0.81%
Gross Profit Growth %	0.02%	0.04%	0%	0.08%	0.05%	0.08%	0.1%	0.04%	0.23%	0.35%
Operating Expenses+	11.33B	11.64B	11.28B	10.79B	11.6B	11.85B	13.07B	13.26B	16.25B	19.12B
OpEx % of Revenue	0.57%	0.55%	0.56%	0.5%	0.52%	0.48%	0.46%	0.46%	0.48%	0.42%
Selling, General & Admin	6.53B	6.33B	6.18B	5.73B	6B	5.87B	6.14B	6.07B	6.94B	8.13B
SG&A % of Revenue	0.33%	0.3%	0.31%	0.27%	0.27%	0.24%	0.22%	0.21%	0.2%	0.18%
Research & Development	4.8B	5.31B	5.1B	5.05B	5.59B	5.98B	6.93B	7.19B	9.31B	10.99B
R&D % of Revenue	0.24%	0.25%	0.26%	0.24%	0.25%	0.24%	0.24%	0.25%	0.27%	0.24%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	3.59B	3.87B	4.25B	6.03B	6B	7.21B	7.93B	8.65B	10.79B	17.5B
Operating Margin %	0.18%	0.18%	0.21%	0.28%	0.27%	0.29%	0.28%	0.3%	0.32%	0.39%
Operating Income Growth %	0.08%	0.08%	0.1%	0.42%	-0%	0.2%	0.1%	0.09%	0.25%	0.62%
EBITDA+	5.02B	5.37B	5.82B	7.63B	7.23B	8.53B	9.48B	10.18B	12.31B	19.27B
EBITDA Margin %	0.25%	0.25%	0.29%	0.36%	0.32%	0.35%	0.33%	0.36%	0.36%	0.43%
EBITDA Growth %	0.07%	0.07%	0.08%	0.31%	-0.05%	0.18%	0.11%	0.07%	0.21%	0.56%
D&A (Non-Cash Add-back)	1.43B	1.5B	1.57B	1.61B	1.23B	1.32B	1.55B	1.52B	1.53B	1.77B
EBIT	2.95B	3.56B	2.53B	3.92B	5.67B	7.59B	6.5B	7.14B	7.04B	13.46B
Net Interest Income+	-74.2M	-76.5M	-58.6M	-83.2M	-320.2M	-326.6M	-314.4M	-268.8M	-312.3M	-605.4M
Interest Income	87M	108.7M	166.4M	159.3M	80.4M	33M	25.4M	62.8M	173.6M	175.2M
Interest Expense	161.2M	185.2M	225M	242.5M	400.6M	359.6M	339.8M	331.6M	485.9M	780.6M
Other Income/Expense	-802.1M	-497.3M	-1.95B	-2.35B	-733.5M	19.1M	-1.78B	-1.85B	-4.23B	-4.82B
Pretax Income+	2.79B	3.37B	2.3B	3.68B	5.27B	7.23B	6.16B	6.81B	6.55B	12.68B
Pretax Margin %	0.14%	0.16%	0.12%	0.17%	0.24%	0.29%	0.22%	0.24%	0.19%	0.28%
Income Tax+	381.6M	636.4M	2.39B	529.5M	628M	1.04B	573.8M	561.6M	1.31B	2.09B
Effective Tax Rate %	0.86%	0.81%	-0.09%	0.88%	1.58%	0.86%	0.91%	0.92%	0.8%	0.84%
Net Income+	2.41B	2.74B	-204.1M	3.23B	8.32B	6.19B	5.58B	6.24B	5.24B	10.59B
Net Margin %	0.12%	0.13%	-0.01%	0.15%	0.37%	0.25%	0.2%	0.22%	0.15%	0.24%
Net Income Growth %	0.01%	0.14%	-1.07%	16.84%	1.57%	-0.26%	-0.1%	0.12%	-0.16%	1.02%
Net Income (Continuing)	2.41B	2.74B	-86.4M	3.15B	4.64B	6.19B	5.58B	6.24B	5.24B	10.59B
Discontinued Operations	0	0	-117.7M	81.4M	3.68B	0	0	0	0	0
Minority Interest	19M	72.8M	75.7M	1.08B	92.2M	183.6M	175.6M	125.6M	91.8M	79.5M
EPS (Diluted)+	2.18	2.49	-0.19	3.13	8.69	6.47	5.85	6.57	5.80	11.71
EPS Growth %	0.01%	0.14%	-1.08%	17.47%	1.78%	-0.26%	-0.1%	0.12%	-0.12%	1.02%
EPS (Basic)	2.18	2.49	-0.19	3.14	8.69	6.47	5.85	6.57	5.83	11.76
Diluted Shares Outstanding	1.11B	1.1B	1.05B	1.03B	957.53M	956.59M	953.65M	950.18M	903.28M	904.06M
Basic Shares Outstanding	1.11B	1.1B	1.05B	1.03B	957.53M	956.59M	953.65M	950.18M	899.38M	900.61M
Dividend Payout Ratio	0.88%	0.79%	-	0.72%	0.29%	0.43%	0.55%	0.57%	0.78%	0.44%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	12.57B	15.1B	19.2B	20.55B	13.71B	17.46B	18.45B	18.03B	25.73B	32.74B
Cash & Short-Term Investments	4.45B	6.04B	8.03B	7.41B	2.44B	3.68B	3.91B	2.21B	2.93B	3.42B
Cash Only	3.67B	4.58B	6.54B	7.32B	2.34B	3.66B	3.82B	2.07B	2.82B	3.27B
Short-Term Investments	785.4M	1.46B	1.5B	88.2M	101M	24.2M	90.1M	144.8M	109.1M	154.8M
Accounts Receivable	4.07B	4.77B	5.26B	5.78B	5.54B	6.93B	8.13B	8.56B	11.34B	13.28B
Days Sales Outstanding	74.46	81.98	96.16	98.1	90.62	103.06	104.75	109.45	121.25	107.58
Inventory	3.45B	3.56B	4.46B	3.1B	3.19B	3.98B	3.89B	4.31B	5.77B	7.59B
Days Inventory Outstanding	249.69	227.68	365.87	241.54	246.68	264.95	193.96	237.27	297.52	329.05
Other Current Assets	0	0	0	2.23B	0	0	0	7.3M	149.5M	111.4M
Total Non-Current Assets+	23B	23.7B	25.78B	23.36B	25.58B	29.17B	30.35B	31.46B	38.28B	45.98B
Property, Plant & Equipment	8.05B	8.25B	8.83B	8B	8.4B	8.68B	8.99B	10.14B	12.91B	17.1B
Fixed Asset Turnover	2.48x	2.57x	2.26x	2.69x	2.66x	2.83x	3.15x	2.81x	2.64x	2.63x
Goodwill	4.04B	3.97B	4.37B	1.37B	3.68B	3.77B	3.89B	4.07B	4.94B	5.77B
Intangible Assets	5.03B	4.36B	4.03B	1.07B	6.62B	7.45B	7.69B	7.21B	6.91B	6.17B
Long-Term Investments	3.65B	5.21B	5.68B	2.02B	1.96B	2.97B	3.21B	2.9B	3.05B	3.22B
Other Non-Current Assets	2.22B	1.91B	2.87B	8.3B	2.34B	3.48B	4.08B	4.34B	4.99B	5.72B
Total Assets+	35.57B	38.81B	44.98B	43.91B	39.29B	46.63B	48.81B	49.49B	64.01B	78.71B
Asset Turnover	0.56x	0.55x	0.44x	0.49x	0.57x	0.53x	0.58x	0.58x	0.53x	0.57x
Asset Growth %	-0.02%	0.09%	0.16%	-0.02%	-0.11%	0.19%	0.05%	0.01%	0.29%	0.23%
Total Current Liabilities+	8.23B	10.99B	14.54B	11.89B	11.78B	12.48B	15.05B	17.14B	27.29B	28.38B
Accounts Payable	1.34B	1.35B	1.41B	1.21B	1.41B	1.61B	1.67B	1.93B	2.6B	3.23B
Days Payables Outstanding	96.97	86.25	115.77	94.11	108.64	106.95	83.38	106.29	133.94	139.99
Short-Term Debt	6.1M	1.94B	3.71B	1.1B	1.5B	8.7M	1.54B	1.5B	6.9B	5.12B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	3.43B	6.61B	7.82B	3.69B	3.1B	9.3B	10.68B	3.91B	16.14B	7.15B
Current Ratio	1.53x	1.37x	1.32x	1.73x	1.16x	1.40x	1.23x	1.05x	0.94x	1.15x
Quick Ratio	1.11x	1.05x	1.01x	1.47x	0.89x	1.08x	0.97x	0.80x	0.73x	0.89x
Cash Conversion Cycle	227.18	223.41	346.26	245.53	228.65	261.06	215.33	240.44	284.84	296.64
Total Non-Current Liabilities+	12.75B	13.74B	18.78B	21.11B	24.81B	28.33B	24.6B	21.58B	25.85B	36.07B
Long-Term Debt	7.97B	8.37B	9.93B	9.2B	13.82B	16.59B	15.35B	14.74B	18.32B	28.53B
Capital Lease Obligations	0	0	0	0	486.7M	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	1.31B	2.19B	2.1B	1.73B	87.3M	0	0
Other Non-Current Liabilities	4.78B	5.37B	8.85B	10.6B	8.32B	9.64B	7.52B	6.75B	7.53B	7.54B
Total Liabilities	20.98B	24.73B	33.31B	33B	36.59B	40.81B	39.65B	38.71B	53.14B	64.44B
Total Debt+	7.98B	10.31B	13.65B	10.3B	15.8B	16.6B	16.88B	16.24B	25.23B	33.64B
Net Debt	4.31B	5.72B	7.11B	2.98B	13.47B	12.94B	13.07B	14.17B	22.41B	30.38B
Debt / Equity	0.55x	0.73x	1.17x	0.94x	5.86x	2.85x	1.84x	1.51x	2.32x	2.36x
Debt / EBITDA	1.59x	1.92x	2.35x	1.35x	2.19x	1.94x	1.78x	1.60x	2.05x	1.75x
Net Debt / EBITDA	0.86x	1.07x	1.22x	0.39x	1.86x	1.52x	1.38x	1.39x	1.82x	1.58x
Interest Coverage	22.28x	20.90x	18.89x	24.85x	14.98x	20.05x	23.35x	26.10x	22.20x	22.42x
Total Equity+	14.59B	14.08B	11.67B	10.91B	2.7B	5.83B	9.15B	10.78B	10.86B	14.27B
Equity Growth %	-0.05%	-0.03%	-0.17%	-0.07%	-0.75%	1.16%	0.57%	0.18%	0.01%	0.31%
Book Value per Share	13.20	12.79	11.09	10.55	2.82	6.09	9.60	11.34	12.03	15.79
Total Shareholders' Equity	14.57B	14.01B	11.59B	9.83B	2.61B	5.64B	8.98B	10.65B	10.77B	14.19B
Common Stock	691.3M	688.5M	687.9M	661M	598.8M	598.2M	596.3M	594.1M	593.6M	592.4M
Retained Earnings	16.01B	16.05B	13.89B	11.4B	4.92B	7.83B	8.96B	10.04B	10.31B	13.54B
Treasury Stock	-90M	-80.5M	-75.8M	-69.4M	-60.8M	-55.7M	-52.7M	-50.5M	-44.2M	-49.5M
Accumulated OCI	-4.58B	-8.29B	-8.73B	-8.74B	-6.52B	-9.51B	-4.34B	-3.84B	-4.33B	-4.32B
Minority Interest	19M	72.8M	75.7M	1.08B	92.2M	183.6M	175.6M	125.6M	91.8M	79.5M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.96B	4.85B	5.62B	5.52B	4.84B	6.5B	7.37B	7.59B	4.24B	8.82B
Operating CF Margin %	0.15%	0.23%	0.28%	0.26%	0.22%	0.26%	0.26%	0.27%	0.12%	0.2%
Operating CF Growth %	-0.34%	0.64%	0.16%	-0.02%	-0.12%	0.34%	0.13%	0.03%	-0.44%	1.08%
Net Income	2.41B	2.74B	-204.1M	3.23B	8.32B	6.19B	5.58B	6.24B	5.24B	10.59B
Depreciation & Amortization	1.43B	1.5B	1.57B	1.61B	1.23B	1.32B	1.55B	1.52B	1.53B	1.77B
Stock-Based Compensation	217.8M	255.3M	281.3M	279.5M	312.4M	308.1M	342.8M	371.1M	628.5M	645.6M
Deferred Taxes	-748.4M	439.5M	-787.9M	326.8M	62.4M	-134.5M	-802.3M	-2.19B	-2.34B	-2.68B
Other Non-Cash Items	798.3M	406.1M	1.55B	2.46B	-3.4B	-444.2M	1.71B	1.63B	2.24B	3.88B
Working Capital Changes	-1.14B	-484.1M	3.2B	-2.38B	-1.69B	-747.4M	-1.01B	-800K	-3.06B	-5.38B
Change in Receivables	-4.99B	-5.09B	-357M	-10.76B	-127.2M	-1.35B	-1.28B	-299.6M	-2.45B	-2.16B
Change in Inventory	-736.3M	-328.2M	-253.9M	7.8M	-258.7M	-533.4M	-235.9M	-599.7M	-1.43B	-2.51B
Change in Payables	461.6M	819M	916.3M	-284.5M	-477.7M	1.27B	-1.01B	1.33B	4.27B	2.61B
Cash from Investing+	26.8M	-3.14B	-3.78B	1.91B	-8.08B	-2.26B	-2.87B	-3.76B	-7.15B	-9.3B
Capital Expenditures	-1.63B	-1.09B	-2.16B	-1.21B	-1.35B	-2.03B	-1.31B	-1.85B	-3.45B	-5.06B
CapEx % of Revenue	0.08%	0.05%	0.11%	0.06%	0.06%	0.08%	0.05%	0.06%	0.1%	0.11%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	5.77B	-56.7M	-175.1M	-2B	-248.7M	102.8M	-644.3M	-1.34B	-2.53B	-3.04B
Cash from Financing+	-2.92B	-559.8M	142.6M	-5.9B	-2.32B	-3.14B	-4.13B	-5.41B	3.5B	1.23B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.13B	-2.16B	-2.19B	-2.31B	-2.41B	-2.69B	-3.09B	-3.54B	-4.07B	-4.68B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	139.2M	-300.8M	-364.4M	-372.8M	-200.1M	-241.6M	-295.9M	-308.9M	-335M	-490.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.34B	3.76B	3.45B	2.51B	3.48B	4.47B	5.39B	4.6B	-3.15B	414.3M
FCF Margin %	0.07%	0.18%	0.17%	0.12%	0.16%	0.18%	0.19%	0.16%	-0.09%	0.01%
FCF Growth %	-0.54%	1.81%	-0.08%	-0.27%	0.39%	0.28%	0.21%	-0.15%	-1.69%	1.13%
FCF per Share	1.21	3.41	3.28	2.42	3.64	4.67	5.65	4.84	-3.49	0.46
FCF Conversion (FCF/Net Income)	1.23x	1.77x	-27.51x	1.71x	0.58x	1.05x	1.32x	1.21x	0.81x	0.83x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	16.07%	19.1%	-1.59%	28.63%	122.26%	145.32%	74.52%	62.67%	48.43%	84.26%
Return on Invested Capital (ROIC)	14%	15%	16.52%	27.67%	29.94%	30.97%	29.03%	27.52%	27.79%	33.69%
Gross Margin	74.76%	73.09%	77.73%	78.22%	78.85%	77.66%	74.18%	76.77%	79.25%	81.31%
Net Margin	12.07%	12.9%	-1.02%	15.04%	37.27%	25.24%	19.71%	21.88%	15.36%	23.51%
Debt / Equity	0.55x	0.73x	1.17x	0.94x	5.86x	2.85x	1.84x	1.51x	2.32x	2.36x
Interest Coverage	22.28x	20.90x	18.89x	24.85x	14.98x	20.05x	23.35x	26.10x	22.20x	22.42x
FCF Conversion	1.23x	1.77x	-27.51x	1.71x	0.58x	1.05x	1.32x	1.21x	0.81x	0.83x
Revenue Growth	1.75%	6.33%	-5.88%	7.61%	3.84%	9.95%	15.4%	0.79%	19.56%	32%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	20.38B	22.69B	25.96B	25.46B	28.81B	40.75B
Product Growth	-	-	-	-	-	11.37%	14.38%	-1.91%	13.16%	41.42%
Collaboration and Other Revenue	-	-	-	-	1.94B	1.84B	2.36B	3.08B	5.31B	4.29B
Collaboration and Other Revenue Growth	-	-	-	-	-	-5.00%	27.94%	30.42%	72.49%	-19.12%
Human Pharmaceutical Products	-	18.06B	19.79B	12.35B	-	-	-	-	-	-
Human Pharmaceutical Products Growth	-	-	9.53%	-37.57%	-	-	-	-	-	-
Animal Health Products	3.18B	3.16B	3.09B	1.62B	-	-	-	-	-	-
Animal Health Products Growth	-	-0.72%	-2.30%	-47.51%	-	-	-	-	-	-
Endocrinology	7.04B	-	-	-	-	-	-	-	-	-
Endocrinology Growth	-	-	-	-	-	-	-	-	-	-
Oncology	3.51B	-	-	-	-	-	-	-	-	-
Oncology Growth	-	-	-	-	-	-	-	-	-	-
Cardiovascular	3.07B	-	-	-	-	-	-	-	-	-
Cardiovascular Growth	-	-	-	-	-	-	-	-	-	-
Neuroscience	2.94B	-	-	-	-	-	-	-	-	-
Neuroscience Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	10.1B	11.51B	12.79B	-	12.72B	14.23B	16.81B	18.19B	21.79B	30.38B
UNITED STATES Growth	-	13.95%	11.11%	-	-	11.84%	18.14%	8.20%	19.80%	39.39%
Europe	3.94B	3.77B	3.94B	4.23B	3.77B	4.19B	4.78B	4.3B	6.17B	6.92B
Europe Growth	-	-4.45%	4.65%	7.30%	-11.02%	11.23%	14.07%	-10.00%	43.62%	12.08%
Non-US	-	3.62B	3.72B	14.64B	-	-	2.7B	2.85B	2.95B	4.27B
Non-US Growth	-	-	2.94%	293.10%	-	-	-	5.54%	3.30%	44.98%
JAPAN	2.03B	2.33B	2.42B	2.49B	2.55B	2.58B	2.37B	1.75B	1.67B	1.81B
JAPAN Growth	-	14.65%	3.81%	3.06%	2.16%	1.39%	-8.37%	-26.18%	-4.28%	8.51%
CHINA	-	-	-	-	-	1.12B	1.66B	1.45B	1.54B	1.66B
CHINA Growth	-	-	-	-	-	-	48.75%	-12.56%	5.98%	7.84%
Other Foreign Countries	3.88B	-	-	-	3.28B	2.42B	-	-	-	-
Other Foreign Countries Growth	-	-	-	-	-	-26.23%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Eli Lilly and Company (LLY) has a price-to-earnings (P/E) ratio of 92.0x. This suggests investors expect higher future growth.

Growth & Financials

Eli Lilly and Company (LLY) reported $59.42B in revenue for fiscal year 2024. This represents a 145% increase from $24.29B in 2011.

Eli Lilly and Company (LLY) grew revenue by 32.0% over the past year. This is strong growth.

Yes, Eli Lilly and Company (LLY) is profitable, generating $18.41B in net income for fiscal year 2024 (23.5% net margin).

Dividend & Returns

Yes, Eli Lilly and Company (LLY) pays a dividend with a yield of 0.48%. This makes it attractive for income-focused investors.

Eli Lilly and Company (LLY) has a return on equity (ROE) of 84.3%. This is excellent, indicating efficient use of shareholder capital.

Eli Lilly and Company (LLY) generated $9.02B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...